Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sutacimig · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants with a FVII(a) level of < 10% | EXPERIMENTAL | - |
| Participants with a FVII(a) level of ≥10% | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Sutacimig | DRUG | Sutacimig is a subcutaneously administered, bispecific antibody being developed as a prophylactic treatment option for congenital bleeding disorders. |
Inclusion Criteria: 1. Age 18 to 60 years, inclusive, at the time of signing informed consent. 2. Diagnosis of FVIID defined by Factor VII:C activity \< 10% documented on ≥ 2 different laboratory measurements by local laboratory assessment. 3. Severe bleeding history characterized by history of a m...
Sutacimig is an investigational small molecule being developed for the treatment of congenital Factor VII deficiency, a rare bleeding disorder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Sutacimig targets Factor VIIa/TLT-1, a molecular complex involved in blood coagulation. By modulating this target, the drug aims to address the underlying clotting defect in patients with congenital Factor VII deficiency.
Sutacimig is being developed by Hemab Therapeutics Holdings, Inc., a biopharmaceutical company. The company's stock is listed under the ticker symbol COAG.
Sutacimig is currently in Phase 2 clinical development. It is an investigational drug and has not received regulatory approval. The drug has been granted Breakthrough Therapy, Fast Track, and Orphan Drug designations by the FDA.
Sutacimig is being evaluated in a Phase 2 clinical trial with the identifier NCT07347249. This study is recruiting participants with congenital Factor VII deficiency in the United Kingdom and aims to enroll 18 adults aged 18 years and older.
No alternative names for Sutacimig have been reported. It is identified solely by its investigational name and is not known to be marketed under any other brand or generic designation.